This is Charles Loprinzi
from Mayo Clinic in Rochester,
I'm happy to talk about
Talking about the incidence,
natural history, measurement,
prevention and treatment aspects.
I'll start off by talking about
the incidence and causative agents.
is a very common problem
who are receiving chemotherapy.
It's probably the most
bothersome chronic toxicity
that we, as oncologists, see
Paclitaxel and oxaliplatin
are two of the biggest offenders,
they cause a fair amount
of neuropathy each time,
and they're used quite frequently.
So I estimate that this is probably
80% of the neuropathy
that we see in clinical oncology.
between the two different drugs.
There are other drugs
that can cause
Other platinum agents
such a cisplatin or carboplatin.
Other taxanes such as docetaxel.
And then there are a variety
of other drugs
and I've listed some there,
that you could see.
These drugs are used less often
than the above noted drugs.
Let me move now
to the natural history
of chemotherapy-induced neuropathy.
I'm gonna illustrate this
with two different drugs,
paclitaxel and oxaliplatin.
Both of them have an acute
and a more chronic form
Let me go with oxaliplatin first
and let me talk about
oxaliplatin acute neuropathy.
This slide illustrates
the acute neuropathy
that's seen with oxaliplatin
by asking patients,
on the day of receiving
and for five days there afterwards,
the amount of troubles they have
to touching cold items,
the most prominent problem,
discomfort swallowing cold items,
and muscle cramps,
the least prominent problem.
And as you can see in this slide,
you should see troubles in the very
first cycle of chemotherapy.
And you see twice as much problem
in cycle two compared to cycle one.
And similar amounts of problem
in cycles three through twelve.